XOFLX™ Lenti Platform: Stable Lentiviral Vector Production Cell Lines Yield LVV Titres Comparable To The Four-Plasmid Process

By M Tridgett, M Mulet, M Raghunath, S Parokkaran Johny, M Ababi, M Peckett, J Kent, R Asatryan, S Dowding, H Gabriel, R Parker-Manuel, Y Dong, M Jiang , R Cawood, C Branciaroli, MI Patrício, and Q Liu

Lentiviral vectors (LVVs) hold immense promise for revolutionizing cell and gene therapy. However, current manufacturing processes remain a significant hurdle, plagued by high costs and inherent variability due to reliance on multi-plasmid transfection. This bottleneck restricts patient access to these potentially life-saving treatments.

This poster studies a groundbreaking solution: XOFLX™, a novel platform of packaging and producer cell lines designed to dramatically enhance LVV manufacturing efficiency. By eliminating the need for separate plasmid preparation and transfection steps, XOFLX™ streamlines the process, reducing both production costs and inherent variability.

Our research meticulously compares LVV production using XOFLX™ cells with the traditional four-plasmid transfection method. We demonstrate that XOFLX™ cells not only keep pace with the current standard but often surpass it, yielding LVVs with comparable or even higher viral titers. Furthermore, XOFLX™ cells ensure the safety and efficacy of the produced LVVs. We have confirmed the absence of replication-competent lentivirus formation within these cells, guaranteeing patient safety. Additionally, transduced primary T cells exhibited robust transgene expression, highlighting the functionality of XOFLX™-produced LVVs for therapeutic applications.

The scalability of XOFLX™ cells adds another layer of advantage. Our research successfully scaled LVV production using XOFLX™ cells to a 1L volume, replicating the efficiency achieved in smaller shake-flask production. This scalability paves the way for large-scale, cost-effective manufacturing of LVVs, a crucial step towards broader patient access to cell and gene therapies.

By streamlining the manufacturing process, reducing costs, and ensuring safety and efficacy, XOFLX™ represents a significant leap forward in LVV production. Examine how this innovative platform has the potential to unlock the full potential of cell and gene therapy, bringing these life-changing treatments to a wider range of patients.